Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.02 +2.17%
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
